文献速递术前评估与围术期医学疼痛医学

加巴喷丁用于大手术后疼痛管理:GAP随机对照试验

Gabapentin for Pain Management after Major Surgery: A Placebo-controlled, Double-blinded, Randomized Clinical Trial (the GAP Study).
PubMed 文献 · Anesthesiology · 2025-07-15

这项多中心、双盲、安慰剂对照随机试验纳入1196例接受心脏、胸科或腹部大手术的成人,比较围术期加巴喷丁(术前600 mg,术后300 mg每日两次共2天)与安慰剂。主要结局住院时间两组相似(加巴喷丁5.94天 vs 安慰剂6.15天;HR 1.07,95%CI 0.95–1.20,P=0.26),严重不良事件比例亦无差异。

要点

  • 大手术围术期加用加巴喷丁未缩短住院时间。
  • 加巴喷丁组与安慰剂组严重不良事件发生率相似。
  • 结果不支持将加巴喷丁常规加入大手术多模式镇痛。

核心结论

  • 在接受心脏、胸科和腹部大手术的患者中,将加巴喷丁加入多模式镇痛方案未改变住院时间或严重不良事件数量。

研究设计与样本

  • 多中心、双盲、安慰剂对照随机临床试验,纳入1196例接受心脏、胸科或腹部大手术的成人。
  • 加巴喷丁组600例,安慰剂组596例;加巴喷丁用法为术前600 mg,术后300 mg每日两次共2天。
  • 主要结局为住院时间,次要结局包括急性和慢性疼痛、阿片类药物总用量、不良健康事件及健康相关生活质量。

主要发现

  • 住院时间中位数两组相似:加巴喷丁5.94天(IQR 4.08–8.04),安慰剂6.15天(IQR 4.22–8.97);HR 1.07,95%CI 0.95–1.20,P=0.26。
  • 384例参与者发生至少一次严重不良事件:加巴喷丁组189/596(31.7%),安慰剂组195/599(32.6%),不同外科专业间存在一定差异。

临床怎么用

  • 大手术围术期加用加巴喷丁不应以缩短住院时间为预期获益。
  • 加巴喷丁未增加严重不良事件,但亦未显示主要结局获益。

局限性

  • 原文未报告次要结局(急慢性疼痛、阿片用量、生活质量)的具体结果。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Gabapentin is an anticonvulsant medication with approval for use in neuropathic pain and epileptic disorders. It is frequently added to multimodal analgesic regimens during and after surgery to reduce opioid use while controlling pain effectively. There is little evidence to show its effectiveness in major surgery. METHODS: In this multicenter, double-blinded randomized controlled trial, adults undergoing major cardiac, thoracic, or abdominal surgery were randomized to receive either gabapentin (600 mg before surgery, 300 mg twice daily for 2 days after surgery) or placebo. The primary outcome was length of hospital stay. Secondary outcomes included acute and chronic pain, total opioid use, adverse health events, and health-related quality of life. Patients were followed up daily in-hospital until discharge and then at 4 weeks and 4 months after surgery. RESULTS: A total of 1,196 participants were randomized (500 underwent cardiac, 346 thoracic, and 350 abdominal surgery); 596 were allocated to placebo, and 600 were allocated to gabapentin. Median length of hospital stay was similar in the two groups (gabapentin, 5.94 [interquartile range (IQR), 4.08 to 8.04] days; placebo, 6.15 [IQR, 4.22 to 8.97] days; hazard ratio, 1.07; 95% CI, 0.95 to 1.20; P = 0.26). Overall, 384 participants experienced one or more serious adverse events (gabapentin, 189 of 596 [31.7%]; placebo, 195 of 599 [32.6%]), with some variation across surgical specialties. CONCLUSIONS: Among patients undergoing major cardiac, thoracic, and abdominal surgery, adding gabapentin to multimodal analgesic regimes did not alter the length of hospital stay or the number of serious adverse events.

来源:Anesthesiology,查看原文。版权归原作者所有。

引用

  1. Baos S, Lui M, Walker-Smith T, et al. Gabapentin for Pain Management after Major Surgery: A Placebo-controlled, Double-blinded, Randomized Clinical Trial (the GAP Study). Anesthesiology. 2025. PMID: 40663783. doi:10.1097/ALN.0000000000005655

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。